31 related articles for article (PubMed ID: 8251653)
1. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.
Romain S; Chinot O; Klijn JG; van Putten WL; Guirou O; Look M; Martin PM; Foekens JA
Br J Cancer; 1994 Aug; 70(2):304-8. PubMed ID: 8054279
[TBL] [Abstract][Full Text] [Related]
3. [Contribution of biology to the therapeutic decision: cancer of the breast in 1995].
Chinot O; Romain S; Martin PM
Bull Cancer Radiother; 1995; 82(2):225-37. PubMed ID: 7546893
[No Abstract] [Full Text] [Related]
4. Protein tyrosine kinase activity as a prognostic parameter in breast cancer, a pilot study.
Bolla M; Rostaing-Puissant BR; Chedin M; Souvignet C; Marron-Charriere J; Colonna M; Berland E; Chambaz EM
Breast Cancer Res Treat; 1993; 26(3):283-7. PubMed ID: 8251653
[TBL] [Abstract][Full Text] [Related]
5. Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results.
Bolla M; Rostaing-Puissant B; Bottari SP; Chedin M; Marron-Charriere J; Colonna M; Berland E; Chambaz E
Breast Cancer Res Treat; 1996; 39(3):327-34. PubMed ID: 8877013
[TBL] [Abstract][Full Text] [Related]
6. Prognostic assessment of PTK activity in T1-T2, N0-N1, M0 breast cancer: a multicentric retrospective study.
Rostaing-Puissant B; Chambaz EM; Romain S; Spyratos F; Daver A; Jourdan ML; Descotes F; Colonna M; Martin PM; Bolla M
Breast Cancer Res Treat; 2002 Jul; 74(2):135-41. PubMed ID: 12186374
[TBL] [Abstract][Full Text] [Related]
7. Protein tyrosine kinase activity in breast cancer and its relation to prognostic indicators.
Kopreski MS; Witters L; Brennan WA; Buckwalter EA; Chinchilli VM; Demers LM; Lipton A
Anticancer Res; 1996; 16(5B):3037-41. PubMed ID: 8920763
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
9. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product.
Ottenhoff-Kalff AE; Rijksen G; van Beurden EA; Hennipman A; Michels AA; Staal GE
Cancer Res; 1992 Sep; 52(17):4773-8. PubMed ID: 1380891
[TBL] [Abstract][Full Text] [Related]
10. Protein measurement with the Folin phenol reagent.
LOWRY OH; ROSEBROUGH NJ; FARR AL; RANDALL RJ
J Biol Chem; 1951 Nov; 193(1):265-75. PubMed ID: 14907713
[No Abstract] [Full Text] [Related]
11. [Estradiol and progesterone receptors in loco-regional breast cancer. Clinical and prognostic correlations].
Bolla M; Chedin M; Chambaz E; Gabelle P
Sem Hop; 1984 Jan; 60(2):91-6. PubMed ID: 6322331
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors.
Delarue JC; Friedman S; Mouriesse H; May-Levin F; Sancho-Garnier H; Contesso G
Breast Cancer Res Treat; 1988 May; 11(2):173-8. PubMed ID: 3401606
[TBL] [Abstract][Full Text] [Related]
13. A thousand and one protein kinases.
Hunter T
Cell; 1987 Sep; 50(6):823-9. PubMed ID: 3113737
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
